Medication info
Crelorba Tablet 20 mg (Rosuvastatin Calcium)

Crelorba Tablet 20 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Kukje Pharmaceutical Co., Ltd.
Appearance
Pink circular film-coated tablet
Packaging
30 tablets (10 tablets/PTP) x 3
Approval status
Active

MFDS item code 201405754 · Approved 2014.12.04 · Insurance code 643703960

Summary

Main use
Improves dyslipidemia, inhibits the progression of atherosclerosis, and prevents cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this product and continue it throughout the treatment period. This product may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this product to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this product to patients with active liver disease. 6. Race: Because systemic exposure to this product is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
Aged 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. Maximum daily dose: 20 milligrams. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individualized according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Kukje Pharmaceutical Co., Ltd.

Efficacy & effects

Improves dyslipidemia, inhibits the progression of atherosclerosis, and prevents cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of premature coronary heart disease
  • stroke risk
View approved original text

This medication is primarily used as an adjunct to diet and exercise when needed for patients with primary hypercholesterolemia and mixed hyperlipidemia. It is also helpful in the treatment of patients with homozygous familial hypercholesterolemia and effectively lowers total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is also utilized as an adjunct to diet in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia who meet certain criteria. It is also applied for the treatment of patients with primary dysbetalipoproteinemia and contributes to reducing cardiovascular disease risk. Specifically, it is effective in lowering the risk of stroke, myocardial infarction, and arterial revascularization. Overall, it is used to improve these factors and promote cardiovascular health.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this product and continue it throughout the treatment period. This product may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this product to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this product to patients with active liver disease. 6. Race: Because systemic exposure to this product is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

Aged 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. Maximum daily dose: 20 milligrams. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individualized according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used by individuals who are allergic to certain components. People with active liver disease or unexplained elevated liver enzyme levels should also avoid this medication. Patients with muscle disease or those taking cyclosporine, as well as individuals with severely impaired kidney function, should avoid this medication. Women who are pregnant or breastfeeding and those of childbearing age who are not using adequate contraception should refrain from using this medication. Those at high risk for myopathy or rhabdomyolysis should particularly avoid high doses (40 mg), especially if they have impaired kidney function, hypothyroidism, or family history. This medication contains lactose, thus should not be taken by individuals with lactose intolerance or related genetic disorders. Those who consume alcohol excessively or have a history of liver disease should have regular liver function tests while on this medication. If symptoms such as muscle pain or weakness occur, notify your healthcare provider immediately, and consider discontinuing use as necessary. In cases of acute severe conditions or severe renal failure, discontinue this medication immediately. Rarely, this medication may lead to severe muscle weakness or ocular myasthenia, and it should be halted immediately if symptoms occur. When combined with other specific medications, the risk of muscle-related side effects may increase, so consult with your healthcare provider regarding concomitant medications. High-dose use may lead to temporary proteinuria, which may require kidney function tests. In Asians, the drug concentration may be higher, necessitating dosage adjustments. In children and adolescents, the effects on growth and secondary sexual characteristics should be considered when deciding on use. Adverse reactions such as interstitial lung disease, severe liver damage, and severe skin reactions have been reported rarely; discontinue if unusual symptoms occur and consult a healthcare provider. This medication can interact with certain drugs, so if you are taking other medications, be sure to inform your healthcare provider and exercise caution. Women who are pregnant or planning to become pregnant should avoid this medication and use suitable contraceptive methods. In cases of overdose, there is no specific antidote, and treatment and liver and muscle function tests should be conducted based on symptoms. Caution should be exercised when driving or operating machinery as dizziness may occur. Although no specific cancer risk has been reported with long-term use of this medication, ongoing observation for adverse reactions during treatment is necessary.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, severe muscle weakness, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, morbilliform drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increase in ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, discomfort in the chest, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture, ideally at room temperature between 1 to 30 degrees Celsius. By doing so, the effectiveness of the medication can be maintained for an extended period.

Appearance and packaging

Appearance

Pink circular film-coated tablet

Package unit

30 tablets (10 tablets/PTP) x 3

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.